We list hundreds of Clinical Trials about "Acquired ImmunoDeficiency Syndrome (AIDS)" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.
More Information about "Acquired ImmunoDeficiency Syndrome (AIDS)" on BioPortfolio
We have published hundreds of Acquired ImmunoDeficiency Syndrome (AIDS) news stories on BioPortfolio along with dozens of Acquired ImmunoDeficiency Syndrome (AIDS) Clinical Trials and PubMed Articles about Acquired ImmunoDeficiency Syndrome (AIDS) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Acquired ImmunoDeficiency Syndrome (AIDS) Companies in our database. You can also find out about relevant Acquired ImmunoDeficiency Syndrome (AIDS) Drugs and Medications on this site too.
GSK has constructed a new HIV immunogen comprised of conserved parts of the HIV virus (gag, pol and nef). The principal objectives of this study are to evaluate the reactogenicity and safety of this candidate vaccine with or without a GSK proprietary adjuvant system at three different doses and to evaluate the CD4+ T-cell response in terms of proportion of responders to the antigens two weeks after the second vaccination.
The purpose of this randomized, double-blinded study is to test the safety of GSK1265744 and how well it works on reducing the amount of HIV in the blood. It will also look at how people react to and how a human body uses GSK1265744. This study will compare the effects of GSK1265744 and placebo. The study will consist of 1 or 2 parts to look at doses of GSK1265744. About 8 people will take part in Part 1 of the study receiving dose A. If additional dosing information is...